MXPA01007359A - Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih. - Google Patents

Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih.

Info

Publication number
MXPA01007359A
MXPA01007359A MXPA01007359A MXPA01007359A MXPA01007359A MX PA01007359 A MXPA01007359 A MX PA01007359A MX PA01007359 A MXPA01007359 A MX PA01007359A MX PA01007359 A MXPA01007359 A MX PA01007359A MX PA01007359 A MXPA01007359 A MX PA01007359A
Authority
MX
Mexico
Prior art keywords
beta
hiv
d4fc
drug
fluorocytidine
Prior art date
Application number
MXPA01007359A
Other languages
English (en)
Inventor
Raymond F Schinazi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MXPA01007359A publication Critical patent/MXPA01007359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA01007359A 1999-01-22 2000-01-21 Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih. MXPA01007359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22
PCT/US2000/001738 WO2000043014A2 (en) 1999-01-22 2000-01-21 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Publications (1)

Publication Number Publication Date
MXPA01007359A true MXPA01007359A (es) 2003-09-22

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01007359A MXPA01007359A (es) 1999-01-22 2000-01-21 Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih.

Country Status (21)

Country Link
EP (1) EP1143976B9 (es)
JP (1) JP2002535278A (es)
KR (1) KR100745408B1 (es)
CN (2) CN101219148A (es)
AT (1) ATE324894T1 (es)
AU (1) AU781281B2 (es)
BR (1) BR0007627A (es)
CA (1) CA2360039C (es)
DE (1) DE60027691T2 (es)
DK (1) DK1143976T3 (es)
ES (1) ES2263449T3 (es)
HK (1) HK1040064B (es)
IL (1) IL144382A (es)
MX (1) MXPA01007359A (es)
NO (1) NO323586B1 (es)
NZ (1) NZ528156A (es)
PL (1) PL198237B1 (es)
PT (1) PT1143976E (es)
RU (1) RU2254133C2 (es)
WO (1) WO2000043014A2 (es)
ZA (1) ZA200105971B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
MXPA06006586A (es) * 2003-12-09 2007-02-21 Pharmasset Inc Metodos de dosificacion para la terapia antiviral con beta-d-2',3'-didesoxi-2',3'-dideshidro-5-fluorocitidina.
WO2005097618A2 (en) 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
EP2266579A1 (en) * 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
EP1089741A1 (en) * 1998-06-24 2001-04-11 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Also Published As

Publication number Publication date
RU2254133C2 (ru) 2005-06-20
EP1143976B9 (en) 2007-02-14
WO2000043014A2 (en) 2000-07-27
ATE324894T1 (de) 2006-06-15
IL144382A0 (en) 2002-05-23
WO2000043014A3 (en) 2000-11-30
KR20020068260A (ko) 2002-08-27
EP1143976A2 (en) 2001-10-17
CA2360039A1 (en) 2000-07-27
CN101219148A (zh) 2008-07-16
BR0007627A (pt) 2002-04-09
HK1040064B (zh) 2006-07-21
CA2360039C (en) 2009-11-24
NO20013599L (no) 2001-09-20
AU781281B2 (en) 2005-05-12
KR100745408B1 (ko) 2007-08-02
CN1337880A (zh) 2002-02-27
PT1143976E (pt) 2006-09-29
ES2263449T3 (es) 2006-12-16
PL198237B1 (pl) 2008-06-30
HK1040064A1 (en) 2002-05-24
AU2627000A (en) 2000-08-07
DK1143976T3 (da) 2006-09-04
DE60027691D1 (de) 2006-06-08
ZA200105971B (en) 2002-10-21
EP1143976B1 (en) 2006-05-03
NO20013599D0 (no) 2001-07-20
WO2000043014A8 (en) 2001-01-18
JP2002535278A (ja) 2002-10-22
NZ528156A (en) 2005-03-24
NO323586B1 (no) 2007-06-11
DE60027691T2 (de) 2007-04-12
IL144382A (en) 2007-02-11

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
BG104727A (en) Pharmaceutical composition of topiramate
JP2002528502A5 (es)
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
MY124465A (en) Reduction of infarct volume using citicoline
MXPA01007359A (es) Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih.
JP2003514025A5 (es)
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
GB9915184D0 (en) Compounds
KR930702985A (ko) 식도암의 치료
JPS62265227A (ja) 薬剤性末梢神経障害の予防・治療剤
James PMPA--first human results
Hargrave et al. 5, 11-dihydro-6 H-dipyrido (3, 2-B: 2, 3'-E)(1, 4) diazepines and their use in the prevention or treatment of HIV infection
Highleyman FDA panel fails to recommend adefovir approval. Food and Drug Administration
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
RU2000104538A (ru) Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal